# US 10,307,436 B2 · Composition containing ginsenoside F1 for removing amyloid plaques

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,436 B2
- Document ID: US10307436B2
- Status: Granted
- Kind: B2
- Application number: 15/193,444
- Filed: 2016-06-27
- Published: 2017-02-02
- Granted: 2019-06-04
- Earliest claimed: 2015-07-27
- Assignees: Intelligent Synthetic Biology Center
- Applicants: Intelligent Synthetic Biology Center
- Inventors: Sun Chang Kim; Jin Hee Han; Bong Hwan Park
- Web page: https://patentgrep.com/patent/US10307436B2

## CPC

- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a food composition and a feed composition for removing amyloid plaques, each composition including ginsenoside F1, in which ginsenoside F1 is effective for removing amyloid plaques in the hippocampal area of the brain.

## Claims

### Claim 1

A method of removing amyloid plaques formed by aggregation of amyloid-beta, comprising the step of administering composition comprising ginsenoside F1 or an acceptable salt thereof to a subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method is used to decrease amyloid plaques twice or more, compared to a subject administered with no ginsenoside F1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition comprises ginsenoside F1 in an amount of 0.01% by weight to 99.9% by weight, based on the total weight of the composition.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition further comprises a sitologically acceptable carrier.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition induces expressions of insulin-degrading enzyme (IDE) and Neprilysin (NPE).

### Claim 6

A method of removing amyloid plaques formed by aggregation of amyloid-beta, comprising the step of administering ginsenoside F1 to a brain cell.